Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 8, 2006, Pages 1247-1255

  Keyvani, L ^a   Murthy, S ^a   Leeson, S ^a   Targownik, L E ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; WARFARIN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; ENDOSCOPY; FEMALE; GASTROINTESTINAL SURGERY; HEMOSTASIS; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT INDICATION; UPPER GASTROINTESTINAL BLEEDING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748896024     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03115.x     Document Type: Article

References (28)

1. Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995; 311: 222-6.
2. Vreeburg EM, Snel P, de Bruijne JW, et al. Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol 1997; 92: 236-43.
3. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995; 90: 206-10.
4. Terdiman JP, Ostroff JW. Risk of persistent or recurrent and intractable upper gastrointestinal bleeding in the era of therapeutic endoscopy. Am J Gastroenterol 1997; 92: 1805-11.
5. Fleischer D. Etiology and prevalence of severe persistent upper gastrointestinal bleeding. Gastroenterology 1983; 84: 538-43.
6. Lewis JD, Bilker WB, Brensinger C, et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002; 97: 2540-9.
7. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-46.
8. Skok P. The epidemiology of hemorrhage from the upper gastrointestinal tract in the mid-nineties - has anything changed? Hepatogastroenterology 1998; 45: 2228.
9. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661-5.
10. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-8.
11. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310-6.
12. Barkun AN, Racz I, Van Rensburg C, et al. Prevention of peptic ulcer rebleeding using continuous infusion pantoprazole vs ranitidine: a multicenter, multinational, randomised, double-blind, parallel group comparison. Gastroenterology 2004; 126: A-78.
13. Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Meta-analysis: Proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005; 21: 677-86.
14. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006; 25 January: CD002094.
15. Barkun A, Bardou M, Marshall JK; Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139: 843-57.
16. Gagnon YM, Levy AR, Eloubeidi MA, et al. Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding. Value Health 2003; 6: 457-65.
17. Chiverton SG, Hunt RH. Relationship between inhibition of acid secretion and healing of peptic ulcers. Scand J Gastroenterol Suppl 1989; 166: 43-7; discussion 74-5.
18. Rockall TA, Logan RF, Devlin HB, et al. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 1996; 347: 1138-40.
19. Longstreth GF, Feitelberg SP. Successful outpatient management of acute upper gastrointestinal hemorrhage: use of practice guidelines in a large patient series. Gastrointest Endosc 1998; 47: 219-22.
20. Andrews CN, Levy A, Fishman M, et al. Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: a multicentre comparative study. Can J Gastroenterol 2005; 19: 667-71.
21. Lau JY, Leung JW, Wu JC, et al. Early administration of high-dose intravenous omeprazole prior to endoscopy in patients with upper gastrointestinal bleeding. A double blind randomized placebo controlled trial. Gastroenterology 2005; 128: A50.
22. Enns R, Andrews CN, Fishman M, et al. Description of prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicentre evaluation. Can J Gastroenterol 2004; 18: 567-71.
23. Cooper GS, Chak A, Lloyd LE, et al. The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage. Gastrointest Endosc 2000; 51 (4 Pt 1): 423-6.
24. Levine JE, Leontiadis GI, Sharma VK, et al. Meta-analysis: The efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002; 16: 1137-42.
25. Daneshmend TK, Hawkey CJ, Langman MJ, et al. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 1992; 304: 143-7.
26. Sung JJ, Chan FK, Lau JY, et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison. Ann Intern Med 2003; 139: 237-43.
27. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997; 336: 1054-8.
28. Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001; 111: 280-4.